&lt;p&gt;High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma&lt;/p&gt;

Lu, Tianzhu; Li, Jieyu; Guo, Qiaojuan; Lin, Wei; Yang, Zheng; Su, Ying; Zong, Jingfeng; Ye, Yunbin

doi:10.2147/ott.s242517

Cited by 9 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple factors, such as Epstein-Barr virus infection, host genetics, and environmental factors contribute to NPC development [ 2 ]. Although after radiotherapy and concurrent adjuvant chemotherapy, clinical outcomes of NPC patients have improved, tumor recurrence and distant metastasis are still a tough challenge [ 3 , 4 ]. Therefore, deeply elucidating the detailed mechanism of NPC development is essential for developing novel therapeutic drugs.…”

Section: Introductionmentioning

confidence: 99%

TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism

et al. 2020

View full text Add to dashboard Cite

Background Nasopharyngeal carcinoma (NPC) is a common malignant tumor. Ten-eleven translocation (TET) protein 2 (TET2), an evolutionarily conserved dioxygenases, is reported to be involved in various malignant tumor developments. Here, we aim to investigate the effect of TET2 on NPC progress in vitro and in vivo, and its detailed underlying mechanism. Methods Real-time PCR and western blotting were used to determine the expression levels of TET1/2/3 in NPC cell lines. The effects of TET2 on NPC progression were evaluated using CCK8 and invasion assays in vitro. Proteins interacted with TET2 in NPC cells were detected by immunoprecipitation and mass spectrometry. The effects of TET2 or pyruvate kinase, muscle (PKM) on glycolysis in NPC cells were examined by detecting glucose uptake and lactate production. The effects of TET2 on NPC progression were evaluated using xenograft tumor model in vivo. Results TET2 expression was decreased in NPC cells, and TET2 overexpression inhibited proliferation and invasion of NPC cells, which is independent on TET2’s catalytic activity. In mechanism, TET2 N-terminal domain interacts with PKM in cytoplasm to prevent PKM dimers from translocating into nucleus, suppressing glycolysis in NPC cells, thereby inhibiting proliferation and invasion of NPC cells. Moreover, using xenograft tumor model, we found that TET2 knockout promoted NPC progression and decreased survival rate. However, administration with the inhibitor of PKM, shikonin, decreased the tumor volume of TET2-cas9 group, and increased the survival rate. Conclusion TET2 suppresses NPC development through interacting with PKM to inhibit glycolysis.

show abstract

Section: Introductionmentioning

confidence: 99%

TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Finally, 31 studies involving 17 tumors and a total of 3,780 patients met our inclusion criteria ( Figure 1 ). The tumor types included in the study were; Nasopharyngeal Carcinoma ( 11 ), Cholangiocarcinoma ( 12 ), lung cancer ( 9 , 10 , 13 – 17 ), Hepatocellular carcinoma ( 20 , 21 , 39 , 40 ), Thyroid carcinoma ( 22 ), Mesothelioma ( 23 ), Colorectal carcinoma ( 24 , 25 ), NK/T cell lymphoma ( 26 , 27 ), Peripheral T-cell lymphoma ( 28 ), Large B-Cell lymphoma ( 29 , 35 ), Hodgkin lymphoma ( 31 ), Ovarian carcinoma ( 32 ), Soft tissue sarcomas ( 33 ), Renal cell carcinoma ( 7 ), Esophageal carcinoma ( 34 ), Gastric carcinoma ( 4 , 35 ), and Pancreatic adenocarcinoma ( 36 , 41 ).…”

Section: Resultsmentioning

confidence: 99%

“…showed that lung cancer patients with high sPD-L1 have an increased risk of death ( 10 ). In gastric cancer and nasopharyngeal carcinoma, there is no correlation between soluble PD-L1 levels and overall survival ( 4 , 11 ). This systematic review and meta-analysis aimed at evaluating the value and clinical significance of sPD-L1 in the survival prognosis of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis

Huang

Zhu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundStudies on the prognostic value of the soluble programmed death ligand 1 (sPD-L1) in cancer patients have not yielded consistent results.ObjectiveThis meta-analysis was performed to assess the association between sPD-L1 and the prognosis of cancer patients.MethodsPublished articles in Pubmed, EMBASE, and Cochrane clinical trial databases were searched from the inception to September 2020. Overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) data were evaluated using a hazard ratio (HR) at 95% confidence interval (95% CI).ResultsA total 31 studies involving 17 tumors and 3,780 patients were included. The overexpression of sPD-L1 was associated with shorter OS (HR 1.85, 95% CI 1.59–2.15, I2 = 33%). High sPD-L1 had worse PFS (HR 2.40, 95% CI 1.55–3.72, I2 = 83%), and worse DFS (HR 2.92, 95% CI 2.02–4.29, I2 = 40%), without significant statistical difference in RFS (HR 2.08, 95% CI 0.99–4.40, I2 = 0%).ConclusionsHigh sPD-L1 levels were associated with worse survival prognosis in cancer patients. The sPD-L1 may be a potential prognostic, non-invasive, and dynamic monitoring biomarker for cancers in the future.

show abstract

“…High levels of soluble LAG-3 or PD-1 in pretreatment serum samples were associated with resistance to ICI treatment in melanoma, and PD-1 serum levels were found increased with treatment in resistance patients. 12 In addition, circulating immune checkpoint proteins have prognostic value in patients with clear cell renal cell cancer, 13 pancreatic adenocarcinoma, 14 and nasopharyngeal carcinoma, 15 with high levels predicting poor survival outcomes. In this case, plasma PD-1, PD-L1, BTLA, and LAG-3 were all increased in the late period of immunotherapy treatment, likely predicting the disease progression.…”

Section: Discussionmentioning

confidence: 99%

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient withROS1-rearranged lung adenocarcinoma

Yue

Qian

Chen

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

Patients with ROS1-rearranged non-small cell lung cancer (NSCLC) inevitably relapse after first-line targeted therapy with tyrosine kinase inhibitors. Efficacy of checkpoint inhibitor-based therapy on ROS1-positive NSCLC in second-line setting and change of immune factors during treatment are rarely studied. We report a ROS1-rearranged stage ⅢB lung adenocarcinoma patient who was resistant to ceritinib after developing a secondary ROS1 F2004L mutation. He received eight cycles of nivolumab plus chemotherapy and had an initial partial response, but brain metastases appeared in the seventh cycle. Lorlatinib was confirmed to have activity against CD74–ROS1 with F2004L in vitro, and was administered to this patient as the third-line therapy. The patient responded well to lorlatinib and had no relapse. We explored the tumor immune microenvironment (TIME) during immune-chemotherapy by multiplex immunohistochemistry, RNA sequencing, and multiplex plasma protein immunoassay. The results show that the TIME was active and plasma inflammatory factors were increased when the patient responded to immune-chemotherapy, while the plasma inhibitory checkpoint proteins, lymphocyte-activation gene 3, B and T lymphocyte attenuator, programmed cell death ligand 1 (PD-L1), and PD-1, were increased when the disease progressed. Moreover, the PD-L1 expression on tumor tissue was upregulated during treatment, predicting the limited benefit from immune-chemotherapy. This case report suggests that lorlatinib is a better choice than immune-chemotherapy in second-line setting for patients with similar genomic characteristics, and that monitoring the immune components during immunotherapy may help to predict disease response.

show abstract

<p>High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma</p>

Cited by 9 publications

References 33 publications

TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism

TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient withROS1-rearranged lung adenocarcinoma

Contact Info

Product

Resources

About